Interacciones de Dextrometorfano

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etiqueta de Anfetamina, Advertencias y precauciones)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans), but also during overdosage situations. (etiqueta de Anfetamina y dexanfetamina, Advertencias y precauciones)

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. (etiqueta de Dextrometorfano, Advertencias)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Belladona y opio, Interacciones medicamentosas)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Buprenorfina, Interacciones medicamentosas)

Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Buprenorfina y naloxona, Interacciones medicamentosas)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs SSRIs, and other serotonergic drugs, including buspirone, alone but particularly with concomitant use of other serotonergic drugs (including triptans), with drugs that impair metabolism of serotonin (in particular, MAOIs, including reversible MAOIs… (etiqueta de Buspirona, Advertencias)

Intervention: Avoid concomitant use Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Butalbital, ácido acetilsalicílico, cafeína y codeína, Interacciones medicamentosas)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Butalbital, paracetamol, cafeína y codeína, Interacciones medicamentosas)

…medical attention if they ‎experience symptoms of hyperalgesia, including worsening pain, increased ‎sensitivity to pain, or new pain [see WARNINGS ; ADVERSE REACTIONS ].‎ Serotonin Syndrome Inform patients that butorphanol tartrate could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Butorfanol, Precauciones)

If serotonin syndrome symptoms occur with the use of other serotonergic drugs, immediately discontinue TONMYA. (etiqueta de Ciclobenzaprina, Interacciones medicamentosas)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etiqueta de Citalopram, Advertencias y precauciones)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Codeína, Interacciones medicamentosas)

• Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etiqueta de Desvenlafaxina, Advertencias y precauciones)

Serotonin Syndrome Serotonin syndrome, a potentially life-threatening reaction, may occur when amphetamines are used in combination with other drugs that affect the serotonergic neurotransmitter systems such as monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), triptans,… (etiqueta de Dexanfetamina, Advertencias)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (etiqueta de Duloxetina, Advertencias y precauciones)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents but also when taken alone. (etiqueta de Escitalopram, Advertencias y precauciones)

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. (etiqueta de Dextrometorfano, Advertencias)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etiqueta de Fentanilo, Advertencias y precauciones)

If concomitant use of PROZAC with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases ( 5.2 ) (etiqueta de Fluoxetina, Advertencias y precauciones)

If concomitant use of Fluvoxamine Maleate Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etiqueta de Fluvoxamina, Advertencias y precauciones)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of granisetron and other serotonergic drugs. (etiqueta de Granisetrón, Advertencias y precauciones)

Example: lactulose Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Hidrocodona, Interacciones medicamentosas)

S er otonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Hidrocodona e ibuprofeno, Precauciones)

Serotonergic drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Hidrocodona y clorfenamina, Interacciones medicamentosas)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Hidrocodona y homatropina, Interacciones medicamentosas)

Serotonin Syndrome Inform patients that hydrocodone bitartrate and acetaminophen tablets could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Hidrocodona y paracetamol, Precauciones)

• Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Hidromorfona, Interacciones medicamentosas)

Combinar la hierba de San Juan (hipérico) con antidepresivos y otros fármacos serotoninérgicos aumenta el riesgo de síndrome serotoninérgico. (NCCIH, St. John's Wort)

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. (etiqueta de Dextrometorfano, Advertencias)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etiqueta de Levomilnaciprán, Advertencias y precauciones)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Levorfanol, Precauciones)

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. (etiqueta de Dextrometorfano, Advertencias)

Serotonin Syndrome: Increased risk when co-administered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etiqueta de Lisdexanfetamina, Advertencias y precauciones)

If concomitant use of lithium with other serotonergic drugs is clinically warranted, inform patients of the increased risk for serotonin syndrome and monitor for symptoms. (etiqueta de Litio, Advertencias y precauciones)

Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etiqueta de Metadona, Advertencias y precauciones)

Serotonin Syndrome: Increased risk when coadministered with serotonergic agents (e.g., SSRIs, SNRIs, triptans), but also during overdosage situations. (etiqueta de Metanfetamina, Advertencias y precauciones)

Serotonin syndrome has resulted from concomitant use of metaxalone (within the recommended dosage range) and other serotonergic drugs [see Warnings and Precautions (5.1) ]. (etiqueta de Metaxalona, Interacciones medicamentosas)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etiqueta de Milnaciprán, Advertencias y precauciones)

Serotonin Syndrome : Increased risk when co-administered with other serotonergic drugs (e.g., SSRI, SNRI, triptans), but also when taken alone. (etiqueta de Mirtazapina, Advertencias y precauciones)

• Serotonergic Drugs: Concomitant use may result in serotonin syndrome. (etiqueta de Morfina, Interacciones medicamentosas)

If concomitant use of olanzapine and fluoxetine capsules with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases ( 5.6 ) (etiqueta de Olanzapina y fluoxetina, Advertencias y precauciones)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Oliceridina, Interacciones medicamentosas)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of Ondansetron Injection and other serotonergic drugs. (etiqueta de Ondansetrón, Advertencias y precauciones)

Serotonergic Drug s: Concomitant use may result in serotonin syndrome. (etiqueta de Oxicodona, Interacciones medicamentosas)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Oximorfona, Interacciones medicamentosas)

Patients should be monitored for the emergence of serotonin syndrome, especially with concomitant use of POSFREA and other serotonergic drugs. (etiqueta de Palonosetrón, Advertencias y precauciones)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Paracetamol y codeína, Precauciones)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etiqueta de Paroxetina, Advertencias y precauciones)

Serotonin Syndrome Inform patients that opioids could cause a rare but potentially life-threatening condition resulting from concomitant administration of serotonergic drugs. (etiqueta de Pentazocina y naloxona, Precauciones)

Serotonergic Drugs : Concomitant use may result in serotonin syndrome. (etiqueta de Prometazina y codeína, Interacciones medicamentosas)

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. (etiqueta de Dextrometorfano, Advertencias)

• Serotonin Syndrome : Potentially life-threatening condition could result from concomitant serotonergic drug administration. (etiqueta de Remifentanilo, Advertencias y precauciones)

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. (etiqueta de Dextrometorfano, Advertencias)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etiqueta de Sertralina, Advertencias y precauciones)

Warnings Do not use if you are now taking a prescription monoamine oxidase inhibitor (MAOI) (certain drugs for depression, psychiatric, or emotional conditions, or Parkinson's disease), or for 2 weeks after stopping the MAOI drug. (etiqueta de Dextrometorfano, Advertencias)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents (e.g., SSRI, SNRI, triptans), but also when taken alone. (etiqueta de Trazodona, Advertencias y precauciones)

If concomitant use of Venlafaxine Extended Release Tablets with other serotonergic drugs is clinically warranted, patients should be made aware of a potential increased risk for serotonin syndrome, particularly during treatment initiation and dose increases. (etiqueta de Venlafaxina, Advertencias y precauciones)

Serotonin Syndrome: Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etiqueta de Vilazodona, Advertencias y precauciones)

• Serotonin Syndrome : Increased risk when coadministered with other serotonergic agents, but also when taken alone. (etiqueta de Vortioxetina, Advertencias y precauciones)

• Serotonin Syndrome : Increased risk when co-administered with other serotonergic agents, but also when taken alone. (etiqueta de Ziprasidona, Advertencias y precauciones)

Use with Other N-methyl-D-aspartate (NMDA) Antagonists The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution. (etiqueta de Memantina, Interacciones medicamentosas)

Use of Memantine with Other N-methyl-D-aspartate (NMDA) Antagonists The combined use of memantine hydrochloride with other NMDA antagonists (amantadine, ketamine, and dextromethorphan) has not been systematically evaluated and such use should be approached with caution. (etiqueta de Memantina y donepezilo, Interacciones medicamentosas)

Serotonergic Drugs The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system, such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that effect the serotonin neurotransmitter system… (etiqueta de Nalbufina, Interacciones medicamentosas)

Although clinical drug interaction studies have not been performed, antimalarial doses (greater than or equal to 600 mg) of quinine may inhibit the metabolism of other drugs that are CYP2D6 substrates (e.g., flecainide, debrisoquine, dextromethorphan, metoprolol, paroxetine ). (etiqueta de Quinina, Interacciones medicamentosas)

Exposure to dextromethorphan, a CYP2D6 substrate, following a single dose of rolapitant increased about 3-fold on Days 8 and Day 22. (etiqueta de Rolapitant, Advertencias y precauciones)

In studies in healthy subjects characterized as extensive metabolizers of dextromethorphan (antitussive drug and CYP2D6 probe substrate), terbinafine increases the dextromethorphan/ dextrorphan metabolite ratio in urine by 16- to 97-fold on average. (etiqueta de Terbinafina, Interacciones medicamentosas)

…and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, gabapentinoids (gabapentin or pregabalin), other opioids, alcohol Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Warnings… (etiqueta de Tramadol, Interacciones medicamentosas)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including clomipramine hydrochloride capsules, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (etiqueta de Clomipramina, Advertencias)

…Syndrome: The development of a potentially life-threatening serotonin syndrome has been reported with serotonin norepinephrine re-uptake inhibitors (SNRIs) and SSRIs, including NORPRAMIN, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (etiqueta de Desipramina, Advertencias)

The safety and efficacy of combination therapy with phentermine and any other drug products for weight loss including prescribed drugs, over-the-counter preparations, and herbal products, or serotonergic agents such as selective serotonin reuptake inhibitors (e.g., fluoxetine, sertraline, fluvoxamine, paroxetine), have not been established. (etiqueta de Fentermina, Advertencias y precauciones)

Such individuals are referred to commonly as “poor metabolizers” of drugs such as debrisoquin, dextromethorphan, and the tricyclic antidepressants. (etiqueta de Nefazodona, Interacciones medicamentosas)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including Pamelor, alone but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (etiqueta de Nortriptilina, Advertencias)

Serotonergic Drugs Clinical Impact: The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome [see Adverse Reaction ( 6.2)]. (etiqueta de Oxicodona y paracetamol, Interacciones medicamentosas)

Ask a doctor before use if you have chronic cough that lasts such as occurs with smoking, asthma, or emphysema cough that occurs with too much phlegm (mucus) Stop use and ask a doctor if cough lasts more than 7 days, comes back, or occurs with fever, rash, or headache that lasts. (etiqueta de Dextrometorfano, Advertencias)

Serotonin Syndrome The development of a potentially life-threatening serotonin syndrome has been reported with SNRIs and SSRIs, including trimipramine capsules, alone, but particularly with concomitant use of other serotonergic drugs (including triptans, tricyclic antidepressants, fentanyl, lithium, tramadol, tryptophan, buspirone, and St. (etiqueta de Trimipramina, Advertencias)

In addition, no dosage adjustment is necessary for substrates of CYP2D6 (e.g., dextromethorphan, fluoxetine, paroxetine, or venlafaxine), CYP2C9 (e.g., warfarin), CYP2C19 (e.g., omeprazole, warfarin), or CYP3A4 (e.g., dextromethorphan) when coadministered with ABILIFY MAINTENA. (etiqueta de Aripiprazol, Interacciones medicamentosas)

Additionally, no dosage adjustment for substrates of CYP2D6 (e.g., dextromethorphan), CYP3A4 (e.g., lovastatin), CYP2B6 (e.g., bupropion), BCRP (e.g., rosuvastatin), or P-gp (e.g., fexofenadine) is required when administered concomitantly with REXULTI. (etiqueta de Brexpiprazol, Interacciones medicamentosas)

Drugs Metabolized by Cytochrome P450 Isozymes In healthy subjects, a subcutaneous dose of 0.3 mg/kg of RELISTOR did not significantly affect the metabolism of dextromethorphan, a CYP2D6 substrate. (etiqueta de Metilnaltrexona, Interacciones medicamentosas)